AIM ImmunoTech Inc. (AIM)
| Market Cap | 22.96M |
| Revenue (ttm) | 193,000 |
| Net Income (ttm) | -20.78M |
| Shares Out | 48.84M |
| EPS (ttm) | -0.43 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 134,300 |
| Open | 0.480 |
| Previous Close | 0.472 |
| Day's Range | 0.453 - 0.490 |
| 52-Week Range | 0.290 - 0.840 |
| Beta | -0.05 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 14, 2023 |
About AIM
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic en... [Read more]
Financial Performance
In 2022, AIM ImmunoTech's revenue was $141,000, an increase of 4.44% compared to the previous year's $135,000. Losses were -$19.45 million, 1.66% more than in 2021.
Financial StatementsNews
AIM ImmunoTech Provides Update Regarding Annual Meeting
OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Company will convene its upcoming 2023 Annual Meeting of Stockholders (the “202...
AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents
Extends certain exclusive U.S. rights to Ampligen for cancer and ME/CFS through 2039 Management discusses patent issuance and what this means in a brief video: here OCALA, Fla., Nov. 28, 2023 (GLOBE N...
AIM ImmunoTech Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
No severe adverse events reported to date Topline data expected as early as Q1 2024 OCALA, Fla., Nov. 21, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) tod...
AIM ImmunoTech Reports Third Quarter 2023 Financial Results and Provides Clinical Pipeline Update
– Highlights continued execution across Ampligen® clinical development programs – Company is well positioned to achieve multiple value-driving milestones during remainder of 2023 and 2024 – Will host ...
AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen in Metastatic Triple-Negative Breast Cancer
OCALA, Fla., Nov. 14, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the publication of results from the Phase 1 study at Roswell Park Compr...
AIM ImmunoTech to Discuss Third Quarter 2023 Financial Results on November 15, 2023 and Host Conference Call and Webcast
OCALA, Fla., Nov. 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that management will host a conference call and webcast to discuss the...
AIM ImmunoTech Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen® for the Treatment of Advanced Recurrent Ovarian Cancer
Data presented at the Society for Immunotherapy of Cancer (SITC) 38 th Annual Meeting Longitudinal comparison of biomarkers in tumor microenvironment showed a gradual, durable response over time in T ...
AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders
OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Company has filed its Definitive Proxy Statement in connection with AIM's upcom...
AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
OCALA, Fla., Oct. 30, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple type...
AIM ImmunoTech Engages Business Development Firm, Azenova, LLC to Catalyze Partnering, Development and Commercialization Efforts for Ampligen® Pipeline Programs
OCALA, Fla., Oct. 17, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced it has entered into an agreement with Azenova, LLC (“Azenova”), a professional business ...
AIM ImmunoTech Selected to Present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
OCALA, Fla., Sept. 22, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced Chris McAleer, Ph.D., Scientific Officer of AIM will present at the 3r...
AIM ImmunoTech Announces Report of Complete Topline Data from Roswell Park Comprehensive Cancer Center Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer
Complete topline results confirm treatment was well tolerated, with promising clinical activity of pathologic complete response (pCR) + microinvasive residual disease (ypTmic) at 66%, comparable to pe...
AIM ImmunoTech to Present at the H.C. Wainwright 25th Annual Global Investment Conference
OCALA, Fla., Sept. 05, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K. Equels, Chief Executive Officer of AIM, will present at...
AIM ImmunoTech Rejects Director Nomination Notice from Activist Group Due to Numerous Material Defects, Omissions and False and Misleading Statements
OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that, after careful deliberation, its Board of Directors (the “Board”) unanimously concl...
AIM ImmunoTech Reports Second Quarter Financial Results and Provides Clinical Pipeline Update
– Continued operational execution across pipeline towards multiple clinical and regulatory value-driving milestones expected in the second half of 2023
AIM ImmunoTech to Discuss Second Quarter 2023 Financial Results on August 15, 2023, and Host Conference Call and Webcast
OCALA, Fla., Aug. 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to discuss the ...
AIM ImmunoTech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
OCALA, Fla., Aug. 08, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced the completion of enrollment in the company's Phase 2 study evaluating Ampligen® as a po...
AIM ImmunoTech Issues Notice that an Unaffiliated Third Party and Organization are Providing False Information Related to Relationship with Company and its Affiliates
OCALA, Fla., July 18, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today issued a notice that the Company has learned that unknown person(s) and/or organi...
AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
Preliminary Ampligen data demonstrates potential to be an effective treatment option for post-COVID conditions Enrollment expected to be completed in Q4 2023 OCALA, Fla., July 10, 2023 (GLOBE NEWSWIRE...
AIM ImmunoTech to Participate in the Virtual Investor Summer Spotlight Series
OCALA, Fla., July 05, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to tr...
AIM ImmunoTech Announces Publication of Positive Findings from a Pre-Clinical Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the American Journal of Cancer Research
Findings support efforts in ongoing Early Access Program and upcoming clinical trials, and suggest Ampligen's potential to reduce tumor cell growth and boost immune response in pancreatic cancer patie...
AIM ImmunoTech Announces Authorizations from Competent Authority and Ethics Board in the Netherlands to Begin a Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer
Ampligen has shown therapeutic synergies with checkpoint inhibitors, potentially increasing survival rates and efficacy
AIM ImmunoTech to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
OCALA, Fla., June 14, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to tr...
AIM ImmunoTech Outlines Recent Significant Progress Across Clinical Development Pipeline and Provides Update on Positive Pre-Clinical and IP Developments
Company's priority oncology clinical programs continue to advance toward key milestones Additional clinical trial site now open at University of Nebraska for Phase 2 study of Ampligen® for the treatme...
AIM ImmunoTech Reports First Quarter Financial Results and Provides Pipeline Update
– Continued execution across pipeline positions AIM to achieve multiple clinical and regulatory value-driving milestones throughout 2023 – Lead clinical program, Phase 2 locally advance pancreatic can...